The global doxorubicin market size attained a value of USD 1378.89 Million in 2025 driven highly by the rising incidences of cancer across the globe. The market is anticipated to grow at a CAGR of 6.40% during the forecast period of 2026-2035 to attain a value of USD 2564.16 Million by 2035.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
6.4%
Value in USD Million
2026-2035
*this image is indicative*
Doxorubicin finds its largest regional market in North America. The region is expected to retain its dominance over the global market in the coming years owing to the increase in cancer incidence and associated mortality rate. The United States registered the highest cancer rate and considerable deaths in 2020. Meanwhile, the regional market in the Asia Pacific is estimated to grow with healthy CAGR over the period owing to the highest mortality rate in China. In terms of application, the most prevalent cancers include breast cancer, prostate cancer, lung cancer, colon and rectum cancer, and skin melanoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hence, the segment of breast cancer is projected to account for the maximum use of the drug in the coming years. According to WHO, the number of breast cancer cases found in the year 2020 was around 2.26 million, which is about 11.7% of all the new cases registered that year.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Doxorubicin (C27H29NO11) is a medication for chemotherapy used in the treatment of various cancer diseases, including breast cancer, bladder cancer, lymphoma, and others. It is administered as an intravenous drug along with other chemotherapy agents and is sold under different brand names including Adriamycin, and Caelyx, among others.
Market Breakup by Application
Market Breakup by Distribution Channel
Market Breakup by Region
The primary driver for the market growth of doxorubicin is the rising incidences of cancer across the globe. This increase can be attributed to the presence of carcinogens in day-to-day use products in the current lifestyle of people. According to the latest statistics provided by the Union for International Cancer Control (UICC), the number of cancer cases has risen to 19.3 million and 10 million cancer related deaths in 2020. This rise is expected to continue in the forthcoming years, providing lucrative opportunities for demand growth of doxorubicin. Additionally, supportive actions from the government for technological progress in clinical diagnostics and therapeutics such as intravenous free therapy and digital microfluidics for biochemical analysis is expected to boost the market growth of the drug over the forecast period. However, it is noteworthy that certain side effects, such as hand-foot syndrome, typhlitis, heart failure, among others, can potentially impede the growing demand.
The report presents a detailed analysis of the following key players in the global doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Globally, doxorubicin market reached a value of USD 1378.89 Million in 2025.
The market is projected to expand at a CAGR of 6.40% from 2026 to 2035, growing to USD 2564.16 Million by 2035.
The market is being driven by the rising cases of cancer and the associated mortality rates, along with an increase in the number of breast cancer patients worldwide.
The industry is primarily being driven the supportive actions from the government for technological progress in clinical diagnostics and therapeutics.
The major regional markets for doxorubicin are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Doxorubicin finds its applications in the treatment of ovarian cancer, multiple myeloma, kaposi sarcoma, leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, and kidney cancer, among other types of cancers.
The major players in the industry are Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., and Cadila Pharmaceuticals Ltd., among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share